Results 231 to 240 of about 24,853 (244)

Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis

Future Oncology, 2022
Haifa Kathrin Al-Ali, Alessandro Maria Vannucchi, Ruben Mesa   +2 more
exaly  

Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib

Journal of Asthma and Allergy, 2022
Benjamin Ungar
exaly  

Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis

Drugs, 2015
Plosker Greg L
exaly  

Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation, 2019
Monzr M Al Malki, Badri Modi, Sanjeet Dadwal   +2 more
exaly  

Ruxolitinib

Reactions Weekly, 2015
openaire   +1 more source

Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro

Cancer Letters, 2013
Wei Duan, Liang Qiao, Lionel Hebbard
exaly  

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Cancer, 2020
Elisabetta Abruzzese, Nicola Sgherza, Elena Maria Elli   +2 more
exaly  

The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers

Journal of Clinical Pharmacology, 2012
Swamy Yeleswaram
exaly  

Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice

Leukemia Research, 2015
Andrei Braester, Noa Lavi, Maya Koren-Michowitz   +2 more
exaly  

<p>Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis</p>

Cancer Management and Research, 2019
Amer M Zeidan, Salma Afifi, Jennifer Zhao   +2 more
exaly